Olmesartan Medoxomil/Amlodipine/Hydrochlorothiazide Teva

Olmesartan medoxil, the active ingredient in Olmesartan Medoxomil/Amlodipine/Hydrochlorothiazide Teva, is a combination antihypertensive presented as a tablet for oral use. It treats high blood pressure in adults, often when monotherapy does not provide adequate control. GNH USA supplies Olmesartan Medoxomil/Amlodipine/Hydrochlorothiazide Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan Medoxil/Amlodipine/Hydrochlorothiazide Teva is manufactured by Teva and distributed by GNH USA under strict quality‑assurance standards.

Olmesartan Medoxil/Amlodipine/Hydrochlorothiazide is indicated for hypertension, a condition of elevated arterial pressure that benefits from multi‑mechanistic blood‑pressure reduction. - Hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk. - Hypertensive urgency (adjunct): may be used with other agents to achieve target pressures when rapid control is needed. - Hypertension with fluid retention: combines a diuretic to address volume overload while controlling vascular tone. - Hypertension in patients who require both an ARB and a calcium‑channel blocker: provides dual pathway blockade for improved efficacy. - Hypertension resistant to monotherapy: offers a single‑pill option that simplifies dosing and improves adherence.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects: - Dizziness or light‑headedness. - Peripheral edema, especially of the ankles. - Headache. - Fatigue or tiredness. - Flushing or warmth sensation. - Increased urination.

Serious or Rare Side Effects: - Severe hypotension or syncope. - Acute kidney injury or worsening renal function. - Hyperkalemia or significant electrolyte imbalance. - Angio‑edema involving the face, lips or airway. - Hepatic dysfunction with elevated transaminases. - Severe skin reactions such as Stevens‑Johnson syndrome.

Before initiating therapy, clinicians should evaluate patient history and monitor relevant parameters. - Renal function: assess baseline creatinine and eGFR, adjust if impaired. - Electrolytes: check serum potassium and sodium before and during treatment. - Cardiovascular status: monitor for symptomatic hypotension, especially in volume‑depleted patients. - Pregnancy: avoid use; drug class is contraindicated in the second and third trimesters. - Concomitant drugs: review for potential additive blood‑pressure lowering effects. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture and direct sunlight.

Olmesartan Medoxil/Amlodipine/Hydrochlorothiazide may interact with several medicines; careful review is advised.

Major Interactions (Avoid): - Dual renin‑angiotensin system blockade (e.g., ACE inhibitors, other ARBs): risk of hyperkalemia and renal impairment. - Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia. - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): increase amlodipine exposure.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect and affect renal function. - Lithium: can increase lithium levels, risking toxicity. - Antidiabetic agents: may require dose adjustment due to enhanced glucose‑lowering effect. - Alcohol: can potentiate orthostatic hypotension. - Loop diuretics: may exacerbate electrolyte disturbances when combined with hydrochlorothiazide.